130 related articles for article (PubMed ID: 33055588)
1. Phase II Adjuvant Cancer-specific Vaccine Therapy for Esophageal Cancer Patients Curatively Resected After Preoperative Therapy With Pathologically Positive Nodes; Possible Significance of Tumor Immune Microenvironment in its Clinical Effects.
Yasuda T; Nishiki K; Hiraki Y; Kato H; Iwama M; Shiraishi O; Yasuda A; Shinkai M; Kimura Y; Sukegawa Y; Chiba Y; Imano M; Takeda K; Satou T; Shiozaki H; Nakamura Y
Ann Surg; 2022 Jan; 275(1):e155-e162. PubMed ID: 33055588
[TBL] [Abstract][Full Text] [Related]
2. Exploratory open-label clinical study to determine the S-588410 cancer peptide vaccine-induced tumor-infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients.
Daiko H; Marafioti T; Fujiwara T; Shirakawa Y; Nakatsura T; Kato K; Puccio I; Hikichi T; Yoshimura S; Nakagawa T; Furukawa M; Stoeber K; Nagira M; Ide N; Kojima T
Cancer Immunol Immunother; 2020 Nov; 69(11):2247-2257. PubMed ID: 32500232
[TBL] [Abstract][Full Text] [Related]
3. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
[TBL] [Abstract][Full Text] [Related]
4. Survival Impact of Total Resected Lymph Nodes in Esophageal Cancer Patients With and Without Neoadjuvant Chemoradiation.
Ho HJ; Chen HS; Hung WH; Hsu PK; Wu SC; Chen HC; Wang BY
Ann Surg Oncol; 2018 Dec; 25(13):3820-3832. PubMed ID: 30284131
[TBL] [Abstract][Full Text] [Related]
5. Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.
Wang H; Tang H; Fang Y; Tan L; Yin J; Shen Y; Zeng Z; Zhu J; Hou Y; Du M; Jiao J; Jiang H; Gong L; Li Z; Liu J; Xie D; Li W; Lian C; Zhao Q; Chen C; Zheng B; Liao Y; Li K; Li H; Wu H; Dai L; Chen KN
JAMA Surg; 2021 May; 156(5):444-451. PubMed ID: 33729467
[TBL] [Abstract][Full Text] [Related]
6. Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens.
Kono K; Iinuma H; Akutsu Y; Tanaka H; Hayashi N; Uchikado Y; Noguchi T; Fujii H; Okinaka K; Fukushima R; Matsubara H; Ohira M; Baba H; Natsugoe S; Kitano S; Takeda K; Yoshida K; Tsunoda T; Nakamura Y
J Transl Med; 2012 Jul; 10():141. PubMed ID: 22776426
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcome of transthoracic esophagectomy with thoracic duct resection: Number of dissected lymph node and distribution of lymph node metastasis around the thoracic duct.
Matsuda S; Takeuchi H; Kawakubo H; Shimada A; Fukuda K; Nakamura R; Takahashi T; Wada N; Kameyama K; Kitagawa Y
Medicine (Baltimore); 2016 Jun; 95(24):e3839. PubMed ID: 27310961
[TBL] [Abstract][Full Text] [Related]
8. [Patterns of recurrence in patients with stage pT3N0M0 thoracic esophageal squamous cell carcinoma after two-field esophagectomy].
Wang Y; Wang L; Yang Q; Li J; He M; Yao J; Qi Z; Li B; Qiao X
Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):48-54. PubMed ID: 26796807
[TBL] [Abstract][Full Text] [Related]
9. Programmed death-1 ligands and tumor infiltrating T lymphocytes in primary and lymph node metastasis of esophageal cancer patients.
Konno-Kumagai T; Fujishima F; Nakamura Y; Nakano T; Nagai T; Kamei T; Sasano H
Dis Esophagus; 2019 Mar; 32(3):. PubMed ID: 30085020
[TBL] [Abstract][Full Text] [Related]
10. Phase II feasibility study of preoperative concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil and elective lymph node irradiation for clinical stage II/III esophageal squamous cell carcinoma.
Hashimoto J; Kato K; Ito Y; Kojima T; Akimoto T; Daiko H; Hamamoto Y; Matsushita H; Katano S; Hara H; Tanaka Y; Saito Y; Nagashima K; Igaki H
Int J Clin Oncol; 2019 Jan; 24(1):60-67. PubMed ID: 30109544
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant Chemoradiotherapy with Cisplatin Plus Fluorouracil for Borderline Resectable Esophageal Squamous Cell Carcinoma.
Suzuki T; Okamura A; Watanabe M; Mine S; Imamura Y; Asari T; Osumi H; Nakayama I; Ichimura T; Ogura M; Ooki A; Takahari D; Yamaguchi K; Chin K
Ann Surg Oncol; 2020 May; 27(5):1510-1517. PubMed ID: 31820213
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients.
Iinuma H; Fukushima R; Inaba T; Tamura J; Inoue T; Ogawa E; Horikawa M; Ikeda Y; Matsutani N; Takeda K; Yoshida K; Tsunoda T; Ikeda T; Nakamura Y; Okinaga K
J Transl Med; 2014 Apr; 12():84. PubMed ID: 24708624
[TBL] [Abstract][Full Text] [Related]
13. Validity of upfront surgery for patients with unsuspected lymph node metastasis in esophageal cancer: a propensity scoring matching study.
Park JK; Kim JJ; Moon SW; Cho DG
J Cardiothorac Surg; 2018 Jun; 13(1):62. PubMed ID: 29880029
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemoradiotherapy followed by esophagectomy for initially resectable squamous cell carcinoma of the esophagus with multiple lymph node metastasis.
Nabeya Y; Ochiai T; Matsubara H; Okazumi S; Shiratori T; Shuto K; Aoki T; Miyazaki S; Gunji Y; Uno T; Ito H; Shimada H
Dis Esophagus; 2005; 18(6):388-97. PubMed ID: 16336610
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of pathological tumor response and residual nodal metastasis in patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery.
Oguma J; Ozawa S; Koyanagi K; Kazuno A; Yamamoto M; Ninomiya Y; Yatabe K
Esophagus; 2019 Oct; 16(4):395-401. PubMed ID: 31190104
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Significance of (18)F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET)-Positive Lymph Nodes Following Neoadjuvant Chemotherapy and Surgery for Resectable Thoracic Esophageal Squamous Cell Carcinoma.
Yasuda T; Yano M; Miyata H; Yamasaki M; Takiguchi S; Fujiwara Y; Doki Y
Ann Surg Oncol; 2015 Aug; 22(8):2599-607. PubMed ID: 25524011
[TBL] [Abstract][Full Text] [Related]
17. Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer.
Kono K; Mizukami Y; Daigo Y; Takano A; Masuda K; Yoshida K; Tsunoda T; Kawaguchi Y; Nakamura Y; Fujii H
Cancer Sci; 2009 Aug; 100(8):1502-9. PubMed ID: 19459850
[TBL] [Abstract][Full Text] [Related]
18. Controlling lymph node micrometastases by neoadjuvant chemotherapy affects the prognosis in advanced esophageal squamous cell carcinoma.
Hiraki Y; Kimura Y; Imano M; Kato H; Iwama M; Shiraishi O; Yasuda A; Shinkai M; Makino T; Motoori M; Yamasaki M; Miyata H; Satou T; Satoh T; Furukawa H; Yano M; Doki Y; Yasuda T
Surg Today; 2021 Jan; 51(1):118-126. PubMed ID: 32596796
[TBL] [Abstract][Full Text] [Related]
19. Post-esophagectomy Adjuvant Chemotherapy Benefits Esophageal Cancer Patients.
Sohda M; Saito H; Kuriyama K; Yoshida T; Kumakura Y; Honjyo H; Hara K; Ozawa D; Suzuki S; Tanaka N; Sakai M; Miyazaki T; Fukuchi M; Kuwano H
In Vivo; 2019; 33(2):501-506. PubMed ID: 30804133
[TBL] [Abstract][Full Text] [Related]
20. Survival risk prediction model for patients with pT
Qi Z; Hu Y; Qiu R; Li J; Li Y; He M; Wang Y
J Cardiothorac Surg; 2021 May; 16(1):121. PubMed ID: 33933129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]